ReviewFrontiers in bioengineering and biotechnology2025
Research progress of nano-based drug delivery systems based on stimuli-responsive materials for the treatment of lung diseases.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the lungs are directly connected to the external environment and have a rich blood supply, they are susceptible to damage and tumor growth. However, the pharmacokinetics of traditional drugs in the lungs are limited when administered orally or intravenously, posing challenges for clinical treatment. Compared to traditional drug delivery methods, nano-based drug delivery systems (NDDSs) have the advantages of high drug loading capacity, strong targeting, low cellular toxicity, and extended circulation time in the blood. Stimuli-responsive materials, often referred to as "smart" materials, are a class of functional materials that can change their properties in response to various stimuli in both internal and external environments. Therefore, stimuli-responsive materials have gradually become promising candidates for NDDSs. To date, many stimuli-responsive NDDSs have been developed for treating lung diseases. Our review primarily summarizes the novel NDDSs that have emerged in recent years for treating common benign and malignant lesions in the lungs, based on stimuli-responsive materials. Finally, we discussed the existing issues in stimuli-responsive NDDSs and looked forward to their future development prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.